# Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients

> **NCT03318835** · PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 162 (estimated)

## Conditions studied

- Thalidomide

## Interventions

- **DRUG:** Thalidomide combined with R-CHOP
- **DRUG:** R-CHOP

## Key facts

- **NCT ID:** NCT03318835
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-22
- **Primary completion:** 2020-08-22
- **Final completion:** 2020-08-22
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2017-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03318835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03318835, "Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03318835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*